Real-World 6-Month Treatment Outcomes of Faricimab in Turkey: The FARTURK Study

Faricimab demonstrated rapid and significant anatomical and functional improvements in 6-month real-world data, evident as early as 15 days after the initial injection, with a safety profile comparable to phase III trials. These findings support faricimab as a potent and reliable therapeutic option in the real-world management of nAMD and DME, though extended follow-up is needed to assess long-term outcomes.

Authors

Institutions

Publication Details

Journal
Ophthalmology and Therapy
Published
2026-02-25
DOI
https://doi.org/10.1007/s40123-026-01338-9
Primary Topic
Rheumatoid Arthritis Research and Therapies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-World 6-Month Treatment Outcomes of Faricimab in Turkey: The FARTURK Study

Nursal Melda Yenerel, Ziya Kapran, Seda Yeşiltaş, Cem Küçükerdönmez et al.
Ophthalmology and Therapy
Rheumatoid Arthritis Research and Therapies
article

Real-World 6-Month Treatment Outcomes of Faricimab in Turkey: The FARTURK Study

Nursal Melda Yenerel, Ziya Kapran, Seda Yeşiltaş, Cem Küçükerdönmez, Sibel Kadayıfçılar, Akın ÇAKIR, Osman Uyar, Fevzi Akkan, tansu erakgün, Sabahattin Sül, Mehmet Türker Bulut, Remzi Avcı, Mehmet Numan Alp, Veysel Levent Karabaş, Şengül Özdek, Selim Doğanay, Hüseyin Dündar, Sinan Emre, Melih Ünal, Doğukan Cömerter, Nigar Şerif, Tahsin Uzundede, Mehmet Çıtırık, Ebru Görgün, Ferşat Muhacir, Esra Vural, Muzaffer Şahin, Mehmet Ali Şekeroğlu, Şefik Can İpek, Figen Şermet, Nilüfer Koçak, Özay Öz, Tuğrul Altan, İhsan Gökhan Gürelik, Göktuğ Seymenoğlu, Gamze Karataş, Mehmet Önen, Aylin Karalezli, Ziya Ayhan, Mahmut Öztürk, Sibel Demirel, Ebru Nevin Çetin, Hakan Özdemir, Ali Hakan Durukan, Mahmut Kaya, Sema Tamer Kaderli, Ali Osman Saatci, Cem Yıldırım, Hüseyin Baran Özdemir
article en

Abstract

Faricimab demonstrated rapid and significant anatomical and functional improvements in 6-month real-world data, evident as early as 15 days after the initial injection, with a safety profile comparable to phase III trials. These findings support faricimab as a potent and reliable therapeutic option in the real-world management of nAMD and DME, though extended follow-up is needed to assess long-term outcomes.

Ophthalmology and TherapyVol. 15(3)
Izmir University (TR), Ankara University (TR), Bilkent University (TR), Dokuz Eylül University (TR), Bezmiâlem Vakıf Üniversitesi (TR), Istanbul Medipol University (TR), Turkish Society of Hematology (TR), Antalya Eğitim ve Araştırma Hastanesi (TR), Güven Hospital (TR), Sağlık Bilimleri Üniversitesi (TR), Denizli Devlet Hastanesi (TR), Istanbul Eye Hospital (TR), Izmir Bozyaka Eğitim ve Araştırma Hastanesi (TR), Ophthalmology Clinic (DE), Dünyagöz Hospital (TR), Retina Clinic (BR), Ulucanlar Göz Eğitim ve Araştırma Hastanesi (TR), Antalya IVF (TR), Kocaeli Üniversitesi (TR), Hacettepe University (TR), Muğla University (TR), Gazi University (TR)
F. Hoffmann-La Roche
Openalex Percentile: Top 46%
Rheumatoid Arthritis Research and Therapies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.